Company continues strong momentum for its comprehensive molecular test for cancer care and driving the era of clinical proteomics by landing first international distributor relationship
CULVER CITY, Calif. & SHOHAM, Israel–(BUSINESS WIRE)–Dec. 6, 2016– NantHealth, Inc., (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, today announced that it has entered into an exclusive reseller agreement for GPS Cancer, the leading molecular test that helps guide treatment strategies including choice of standard chemotherapy for oncologists, with Oncotest-Teva, a pioneer in the field of personalized medicine and a subsidiary of Teva Pharmaceutical Industries Ltd. in Israel. This landmark agreement—which expands the GPS Cancer footprint globally—adds a key international distributor to the growing set of health plans, health systems, and Fortune 50 companies that have committed to covering or using GPS Cancer since its commercial availability in June 2016.
“This is a ground-breaking partnership with Oncotest-Teva, and it builds on the growing momentum we’ve had with payers, providers, and self-insured employers in the United States by bringing GPS Cancer globally,” said Patrick Soon-Shiong, MD, CEO of NantHealth. “Cancer is a devastating disease, not only in the United States, but across the globe. This opportunity to partner with Oncotest-Teva for GPS Cancer truly puts into perspective the depth of our mission—to fight cancer worldwide and to evolve from the era of genomics into the 21st century of quantitative proteomics. With GPS Cancer tests now available in Israel, our goal of expanding treatment options for patients beyond the U.S. is becoming a reality. We’re looking forward to bringing patients—no matter where they are—the opportunity to receive personalized care and better informed decision making even when deciding on standard chemotherapy.”
Under the terms of the agreement, Oncotest-Teva will have exclusive rights to distribute GPS Cancer to physicians in Israel. GPS Cancer, which integrates quantitative proteomics with whole genome (DNA) and transcriptome (RNA) sequencing, is the only integrated comprehensive molecular test of its type conducted in CLIA-certified and CAP-accredited laboratories. It provides oncologists with a comprehensive molecular profile of a patient’s cancer to inform personalized treatment strategies. As a cornerstone of the Cancer MoonShot 2020 program, GPS Cancer provides key insights based on the unique biology of a patient’s tumor—from the DNA to the RNA to the protein. This rich information helps doctors build more effective treatment plans based on FDA-approved drugs and active clinical trials, while enabling cancer researchers to design new clinical trials that harness the potential of the immune system.
“Oncotest-Teva is continuously striving to bring oncologists in Israel the highest quality solutions to understand diseases that will help them provide patients with better treatments and outcomes,” said Dr. Lior Soussan-Gutman, managing director at Oncotest-Teva. “GPS Cancer raises the bar when it comes to advanced care options. This partnership is not only fantastic for our team to be able to bring GPS Cancer tests to local oncologists, but it’s truly an opportunity to offer patients a new standard of care—one that is personalized and has been favorable amongst other cancer care providers as seen with the Cancer MoonShot 2020 program.”
Unlike other tests on the market, GPS Cancer sequences the whole genome of 20,000+ genes and 3 billion base pairs and matches against the patient’s normal DNA, providing oncologists with an expansive view of alterations to inform personalized treatment strategies. GPS Cancer extends from genomics to proteomics not only through analysis of RNA, but also utilizes quantitative proteomics through mass spectrometry to measure the amounts of clinically relevant proteins that are the targets of or essential for various therapeutics. This clinically relevant information helps oncologists to better understand how patients may potentially respond to chemotherapies, targeted therapies and immunotherapies.
Cautionary Note Concerning Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the capabilities and anticipated utility of our GPS Cancer, including predicting patient response and resistance to therapeutics, enabling diagnoses by physicians and accelerating efforts to bring novel combinations of therapeutic agents to cancer patients, as well as our contribution to the Cancer 2020 initiative. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results. Factors that may cause future results to differ materially from management’s current expectations include, among other things, that GPS Cancer may not perform as anticipated, that sufficient physicians may not adopt GPS Cancer to assist their diagnoses or that healthcare payers may not provide reimbursement for GPS Cancer as expected. Our business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of our products; our ability to successfully launch new products and applications; competition; our sales, marketing and distribution capabilities; our planned sales, marketing, and research and development activities; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting our business and operating results can be found in our existing and future filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements except as may be required by law.
About NantHealth, Inc.
NantHealth, Inc. a member of the NantWorks ecosystem of companies, is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth‘s unique systems-based approach to personalized healthcare applies novel diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with large-scale, real-time biometric signal and phenotypic data to track patient outcomes and deliver precision medicine. For nearly a decade, NantHealth has developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets billions of molecular, clinical, operational and financial data points derived from novel and traditional sources, continuously improves decision-making and further optimizes our clinical pathways and decision algorithms over time. For more information please visit www.nanthealth.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
About GPS Cancer™
GPS Cancer™ is a comprehensive molecular profile available through NantHealth. GPS Cancer integrates whole genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and quantitative proteomics through mass spectrometry, providing oncologists with unprecedented insight into the molecular signature of each patient’s cancer to inform personalized treatment strategies. GPS Cancer profiling is conducted in CLIA-certified and CAP-accredited laboratories, and is a key enabler for Cancer MoonShot 2020, the world’s most comprehensive cancer collaborative initiative seeking to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients. For more information, visit www.gpscancer.com and www.cancermoonshot2020.org.
Oncotest-Teva is a pioneer in the field of personalized medicine in Israel. For almost two decades, Oncotest-Teva has been focusing on identification of novel approaches to diagnosing malignant diseases and predicting the course of disease, according to the unique genetic profile of the patient and tumor cells, and more precise and more effective matching of therapeutic directions.
Jen Hodson, 562-397-3639